CORRECTION

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium

T Goranova1, D Ennis2, A M Piskorz1, G Macintyre1, L A Lewsley3, J Stobo3, C Wilson3, D Kay4, R M Glasspool5, M Lockley6,7, E Brockbank6, A Montes8, A Walther9, S Sundar10, R Edmondson11, G D Hall12, A Clamp13, C Gourley14, M Hall15, C Fotopoulou16, H Gabra16, S Freeman17, L Moore17, M Jimenez-Linan17, J Paul9, J D Brenton1,17 and I A McNeish2,5 on behalf of the BriTROC investigators

British Journal of Cancer (2019) 120:868; https://doi.org/10.1038/s41416-019-0433-6

Correction to: British Journal of Cancer 116,1294–1301; https://doi.org/10.1038/bjc.2017.86; published online 30 March 2017

This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019

1Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK; 2Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; 3Cancer Research UK Clinical Trials Unit, Glasgow G12 0YN, UK; 4Department of Radiology, Gartnavel General Hospital, Glasgow G12 0YN, UK; 5Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK; 6Barts Cancer Institute, London EC1M 6BQ, UK; 7University College Hospital, London WC1E 6BT, UK; 8Gly’s Hospital, London SE1 9RT, UK; 9Bristol Haematology and Oncology Centre, Bristol BS2 8ED, UK; 10City Hospital, Birmingham B18 7QH, UK; 11St Mary’s Hospital, Manchester M13 9WL, UK; 12St James Hospital, Leeds LS9 7TF, UK; 13The Christie Hospital, Manchester M20 4BX, UK; 14Edinburgh Cancer Research Centre, Edinburgh EH4 2XR, UK; 15Mount Vernon Cancer Centre, Northwood HA6 2RN, UK; 16Imperial College, London W12 OHS, UK and 17Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK

Correspondence: J D Brenton (james.brenton@cruk.cam.ac.uk) or I A McNeish (iain.mcneish@glasgow.ac.uk)

Published online: 13 March 2019

© The Author(s) 2019 Published by Springer Nature on behalf of Cancer Research UK